According to a presentation at the 2012 Gastrointestinal Cancers Symposium by investigators at Johns Hopkins University, an experimental pancreas cancer vaccine is boosting survival times of this rapidly fatal cancer.
The presentation, “Phase 1b Study of Ipilimumab Alone or in Combination with Allogeneic Pancreatic Tumor Cells Transfected with a GM-CSF Gene in Pancreatic Cancer,” highlighted BioSante Pharmaceuticals' Phase Ib clinical study results, which demonstrated that the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma could be increased from 3.3 months with ipilimumab alone to 5.5 months with the combination of ipilimumab and BioSante's vaccine GVAX.
This Phase Ib clinical study involved 30 patients and was initially carried out to measure safety and efficacy only.
The combination IPI/GVAX also boosted one year survival, from 7 % to 27 %, encouraging the company to begin plans for a multi-center clinical study later this year.
Source: Therapeutics Daily
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
